Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

3.045 -0.105 (-3.33%)
Streaming Delayed Price Updated: 10:46 AM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 Next >
News headline image
Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Rezolute, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
From Pomerantz LLP
Via GlobeNewswire
News headline image
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
From Pomerantz LLP
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
From Pomerantz LLP
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
From Hagens Berman
Via Business Wire
News headline image
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
From DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
Webcast scheduled for Monday, November 10 at 12:00 pm EST 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.